Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) have announced that the National Institute for Health and Care Excellence (NICE), a non-departmental public body of the Department of Health in the United Kingdom, issued a second draft guidance on the use of PIXUVRI(®) (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (patients with aggressive B-cell NHL who failed 2 or 3 prior lines of therapy)...
More...
More...